Nuclera launches antibody triage service to advance AI-driven antibody discovery

Rapid binder triage, of AI-driven candidate sets, enables early elimination of non-binders ahead of costly downstream workflowsPowered by cell-free technology to convert AI-generated candidates into experimental binding data

Cambridge, UK and Bo

Nuclera launches GPCR-focused nanodisc panel to streamline membrane protein production

Enables expression of active GPCRs in 48 hoursPanel supports screening to scale-up on eProtein Discovery

Cambridge, UK, and Boston MA, USA, 30 March 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins

Nuclera and leadXpro partner to accelerate structure-based drug design for complex membrane proteins

Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targetsTo de-risk and shorten path to critical structural and biophysical insights that inform structure-based drug design

Cambridge, UK, Boston MA, USA and Vi

Nuclera extends Series C funding to $87M to advance antibody engineering

Additional $12M financing led by Elevage Medical Technologies and Jonathan Milner alongside existing investors British Business Bank, and GK GohThe funding will accelerate development of eProtein Discovery for full-format antibody expression, purification, and binding v

Nuclera eProtein Discovery System installed at leading Universities in Taiwan

Installations at National Taiwan University and National Cheng Kung University expand Nuclera’s global footprint with first commercial sales in AsiaSystem strengthens Taiwan’s capabilities in protein drug discovery research

Cambridge, UK, and Bo

Nuclera expands access to eProtein Discovery for APAC customers with distributor agreement in Australia and New Zealand

Partnership with Solve Scientific strengthens international sales as part of ongoing global expansion 

Nuclera and Cytiva collaborate to accelerate characterization of proteins for drug development

Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactionsCollaboration allows researchers to progress rapidly from DN

Nuclera establishes distribution network across APAC and the Middle East

Operational expansion accelerates global distribution capability to increase regional access and technical supportMultiple partnerships establish direct distribution channels in China, Japan, South Korea, Singapore and Israel

Cambridge, UK, and

Nuclera expands eProtein Discovery capabilities to enable membrane protein production

Membrane proteins synthesized and purified within 48 hours. Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized

Cambridge, UK, and Boston MA, USA, 14 April 2025: Nuclera, the biotechnology company

Nuclera appoints Seth Benson as Chief Financial Officer

Appointment to drive commercial growth of eProtein Discovery and support strategic expansion

Nuclera appoints William J. Kullback as Non-Executive Director

Appointment of leading financial executive supports continued commercial development Current CFO at Telesis Bio, former CFO of BioLegend Inc.

Cambridge, UK, 18 February 2025: Nuclera, the biotechnology company accelerating protein

Nuclera’s eProtein Discovery system installed at Domainex to streamline protein production services

Domainex is the first CRO to have installed the eProtein Discovery system Installation of Nuclera’s technology expands Domainex’s protein production services

Cambridge, UK, 04 November 2024: Nuclera, the biotechnology company ac

Nuclera closes $75 million USD financing

Series C round led by Elevage Medical Technologies. Funding will accelerate the commercialization of Nuclera’s eProtein Discovery platform, to optimize protein expression and purification workflows within research labs globally.

Nuclera strengthens team with three key appointments

Dr Gordon McInroy appointed as COO, Dr Tobias Ost as SVP Product Development, and Charu Maini as SVP of People

Nuclera awarded £1.14M Innovate UK funding for development of eProtein Discovery

£790k FASST grant, in collaboration with DeepMirror, and £350k Engineering Biology grant awarded for platform development.

Nuclera eProtein Discovery system installed at leading academic institutes

11 installs successfully completed Novel platform automates and accelerates protein production, enabling scale-up to mg amount in less than 48 hours List of institutes includes, University College London, University of Cambridge, University of Sout

Nuclera Joins Tech Nation’s Future Fifty Program

Nuclera recognized as one of UK’s most exciting growth stage companies Official launch of 2024 cohort taken place at 10 Downing Street

Cambridge, UK, 19 March 2024: Nuclera, the biotechnology company enabling rapid protein expres

Nuclera appoints Joseph Bertelsen as Chief Commercial Officer

Key appointment to lead global commercial launch of eProtein Discovery platform